GSA Capital Partners’s Juno Therapeutics, Inc. JUNO Stock Holding History

GSA Capital Partners’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-20,500	Closed	-$901K	–	2065
2015 Q4	$901K	Buy	+20,500	New	+$1.02M	0.04%	777
2015 Q3	–	Sell	-54,700	Closed	-$2.92M	–	2187
2015 Q2	$2.92M	Buy	+54,700	New	+$2.9M	0.11%	182

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GSA Capital Partners's JUNO Position: Q1 2016 in Review

GSA Capital Partners sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2016, closing a stake of 20,500 shares — an estimated $901K sold.

GSA Capital Partners first reported a position in JUNO in Q2 2015 and held it in 2 quarters. The position peaked at $2.92M in Q2 2015. 158 funds tracked by Wall St. Rank hold JUNO as of Q1 2016.

GSA Capital Partners reported no remaining Juno Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
GSA Capital Partners sold 20,500 Juno Therapeutics, Inc. shares in Q1 2016, an estimated $901K.
GSA Capital Partners first reported a position in Juno Therapeutics, Inc. in Q2 2015 and held it in 2 quarters.
GSA Capital Partners's Juno Therapeutics, Inc. position peaked at $2.92M in Q2 2015.
158 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2016.

Based on GSA Capital Partners's 13F filing for Q1 2016, filed 11 May 2016.